News

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, regrets to announce that Dr Irina Antonijevic (CMO) will return to Boston as a result of a family health issue.

vasopharm GmbH today announced the completion of a Phase 1 safety study on its late stage asset, VAS203. This study was conducted in support of the ongoing pivotal Phase III (NOSTRA III) trial of moderate to severe traumatic brain injury, which is currently running in 25 European centres.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer. In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced that the first patient has been enrolled in to the NOSTRA III (NO Synthase in TRAumatic Brain Injury) trial – a phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced it has successfully raised EUR 20 million of new capital. The financing was co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor, UK based Fort Rock Capital. Existing investors Bayern Kapital and funds advised by Hanseatic Asset Management LBG also participated in the round. Dr Mario Alberto Accardi, Venture Partner at Fort Rock Capital will be joining the Board of the company as a Non-Executive Director.